Dividend policy has taken the spotlight again among the investors’ discussions in the U.S. With one month into 2026, insider behavior might just be a reliable tool for making investment decisions.

AI adoption is fundamentally shaped by the readiness of both human capital and organizational processes, not merely by financial investment,” said John-David Lovelock, Distinguished VP Analyst at ...

George Soros Boosts Stake In Tesla, Opens $35M Position In Broadcom In Q4 Despite Macro Headwinds (International Business Times) Bill Ackman’s Pershing Powers Through AI Selloff With A Big Bet Worth ...

For over 10 years, U.S. equities have dominated global markets, but that leadership is beginning to show signs of fatigue in 2025. Valuation gaps illustrate the shift: U.S.

Entertainment stocks are back in the conversation as investors look beyond the narrow list of sectors that defined much of ...

In this era of global technology transformation, software companies have had their fair share of traction, and rightly so!

On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 ...

On January 20, the price target on Soleno Therapeutics (NASDAQ:SLNO) was increased from $110 to $120 by Ram Selvaraju from ...

On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT).

As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish.

As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment.

On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock.